<DOC>
	<DOCNO>NCT00599781</DOCNO>
	<brief_summary>This study investigate safety efficacy different gene therapy approach Severe Combined Immunodeficiency ( SCID ) cause deficiency adenosine deaminase ( ADA ) enzyme . This severe condition cure HLA-matched sibling donor bone marrow transplantation . Patients enrol HLA-identical sibling donor available patient show evidence failure enzyme replacement therapy treatment long-term available option . The aim study evaluate safety efficacy procedure identify relative role peripheral blood lymphocyte hematopoietic stem cell progenitor cell long-term reconstitution immune function retroviral vector mediate ADA gene transfer .</brief_summary>
	<brief_title>Gene Therapy ADA-SCID</brief_title>
	<detailed_description>This mono-centric , non-randomized , non-controlled , open label , phase I-II trial evaluate safety efficacy ADA gene transfer somatic cell treatment ADA-SCID</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<criteria>Lack HLAidentical sibling donor Evidence failure enzyme replacement treatment &gt; 6 month PEGADA available life long option HLA identical bone marrow sibling donor HIV infection Malignancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>adenosine deaminase</keyword>
	<keyword>SCID</keyword>
	<keyword>gene therapy</keyword>
	<keyword>retroviral vector</keyword>
</DOC>